Iovance Biotherapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell IOVA and other ETFs, options, and stocks.About IOVA
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors.
CEOFrederick G. Vogt
CEOFrederick G. Vogt
Employees838
Employees838
HeadquartersSan Carlos, California
HeadquartersSan Carlos, California
Founded2007
Founded2007
Employees838
Employees838
IOVA Key Statistics
Market cap581.05M
Market cap581.05M
Price-Earnings ratio-1.43
Price-Earnings ratio-1.43
Dividend yield—
Dividend yield—
Average volume27.17M
Average volume27.17M
High today$1.79
High today$1.79
Low today$1.66
Low today$1.66
Open price$1.69
Open price$1.69
Volume14.35M
Volume14.35M
52 Week high$12.51
52 Week high$12.51
52 Week low$1.65
52 Week low$1.65
IOVA News
Simply Wall St 3d
News Flash: 12 Analysts Think Iovance Biotherapeutics, Inc. Earnings Are Under ThreatThe analysts covering Iovance Biotherapeutics, Inc. ( ) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutor...
TipRanks 6d
Iovance Biotherapeutics’ Earnings Call: Mixed Sentiments and Future ProspectsIovance Biotherapeutics ((IOVA)) has held its Q1 earnings call. Read on for the main highlights of the call. The recent earnings call of Iovance Biotherapeutic...
Analyst ratings
69%
of 13 ratingsBuy
69.2%
Hold
30.8%
Sell
0%
People also own
Based on the portfolios of people who own IOVA. This list is generated using Robinhood data, and it’s not a recommendation.